Neurotech, a developer of active implantable devices, has received CE mark approval for its ADNS-300 to treat refractory epilepsy.
The surgically implanted ADNS-300 system operates as a pacemaker to produce stimulation towards the brain by delivering mild electrical pulses to the vagus nerve in the neck.
In addition to the nerve stimulation, the ADNS-300 system uses a cuff electrode to record neural activity from the left vagus nerve.
Neurotech CEO Michel Troosters said the medical device will prove to be an important tool in the care for patients suffering from refractory epilepsy.
"The sensing feature, once clinically validated, could represent a paradigm shift in the VNS field," Troosters added.
The ADNS-300 stimulator is also used in Advens therapy as a therapeutic option for patients who are refractory to anti-epileptic drugs and are not eligible for epilepsy surgery.